Utility of procalcitonin, C-reactive protein and white blood cells alone and in combination for the prediction of clinical outcomes in community-acquired pneumonia by Zhydkov, Andriy et al.
Clin Chem Lab Med 2015; 53(4): 559–566
Andriy Zhydkov, Mirjam Christ-Crain, Robert Thomann, Claus Hoess, Christoph Henzen, 
Werner Zimmerli, Beat Mueller and Philipp Schuetz*, for the ProHOSP Study Group
Utility of procalcitonin, C-reactive protein and 
white blood cells alone and in combination for 
the prediction of clinical outcomes in community-
acquired pneumonia
DOI 10.1515/cclm-2014-0456
Received April 28, 2014; accepted June 13, 2014; previously published 
online July 11, 2014
Abstract
Background: The added value of biomarkers, such as pro-
calcitonin (PCT), C-reactive protein (CRP), and white blood 
cells (WBC), as adjuncts to clinical risk scores for predicting 
the outcome of patients with community-acquired pneu-
monia (CAP) is in question. We investigated the prognostic 
accuracy of initial and follow-up levels of inflammatory 
biomarkers in predicting death and adverse clinical out-
comes in a large and well-defined cohort of CAP patients.
Methods: We measured PCT, CRP and WBC on days 1, 3, 5, 
and 7 and followed the patients over 30 days. We applied 
multivariate regression models and area under the curve 
(AUC) to investigate associations between these biomark-
ers, the clinical risk score CURB-65, and clinical outcomes 
[i.e., death and intensive care unit (ICU) admission].
Results: Of 925 patients with CAP, 50 patients died and 
118 patients had an adverse clinical outcome. None of 
the initial biomarker levels significantly improved the 
CURB-65 score for mortality prediction. Follow-up bio-
marker levels showed significant independent association 
with mortality at days 3, 5, and 7 and with improvements 
in AUC. Initial PCT and CRP levels were independent prog-
nostic predictors of adverse clinical outcome, and levels of 
all biomarkers during the course of disease provided addi-
tional prognostic information.
Conclusions: This study provides robust insights into the 
added prognostic value of inflammatory markers in CAP. 
Procalcitonin, CRP, and to a lesser degree WBC provided 
some prognostic information on CAP outcomes, particu-
larly when considering their kinetics at days 5 and 7 and 
when looking at adverse clinical outcomes instead of mor-
tality alone.
Keywords: community-acquired pneumonia (CAP); 
C-reactive protein (CRP); CURB-65 score; mortality; pro-
calcitonin; severity of illness; white blood cells.
Introduction
Community-acquired pneumonia (CAP) continues to be 
a worldwide health problem, particularly as a leading 
source of infections with high mortality [1]. The inci-
dence of CAP in Europe ranges from 1.2 to 11.6 cases per 
1000 population per year [2] with rates of hospitalization 
ranging from 40% to 60% [3]. Although the elderly and 
patients with comorbidities have a 10-fold higher risk for 
CAP, sporadic viral pneumonia can sometimes be fatal in 
over 50% of younger patients 10–39 years of age [4, 5].
Diagnosis, severity assessment, and prediction of 
outcome in patients with CAP are challenging and often 
based on clinical experience, and not on scientific evi-
dence. Clinical severity scores, such as the pneumonia 
severity index (PSI), the ‘confusion, urea, respiratory, 
and blood pressure’ (CURB) score, and its modification 
the CURB-65 (CURB plus age  > 65), may provide a more 
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objective initial severity assessment for mortality pre-
diction and are thus recommended by guidelines [6]. 
However, these scores have important limitations, such 
as only moderate prognostic accuracy, validation only 
for mortality but not for other adverse clinical outcomes, 
and lack of inclusion of novel biomarkers reflecting the 
inflammatory response and/or infection severity. Several 
smaller studies have suggested that the addition of bio-
markers, such as C-reactive protein (CRP) [7] and pro-
calcitonin (PCT) [8] may further improve these scores. 
However, most previous studies had small sample sizes 
and/or were limited to measurement of biomarkers only 
once upon admission.
The aim of the current analysis was to take advantage 
of a large multicenter cohort to investigate the prognos-
tic value of levels of these biomarkers and white blood 
cells (WBC) both at admission and during follow-up as 
adjuncts to the CURB65 score for prediction of mortality 
and adverse clinical outcomes.
Materials and methods
Setting and study population
The present study analyzed data from the procalcitonin guided anti-
biotic therapy and hospitalization in patients with lower respiratory 
tract infections (ProHOSP) study using 925 patients with radiologi-
cally confirmed CAP. A detailed description of this study has been 
published elsewhere [9, 10] and is also available in the clinicaltrials.
gov database (NCT00350987). Full ethical approval for this trial was 
obtained from all Local Ethical Committees, and all patients gave 
written informed consent.
In brief, patients with lower respiratory tract infections (LRTI) 
including CAP admitted to emergency departments at 1 out of 6 hos-
pitals in Switzerland between December 2006 and March 2008 were 
consecutively included. A study website provided information on the 
evidence-based management of all patients based on the most recent 
guidelines [6, 11]. For all patients with CAP, the study protocol explic-
itly specified the need for X-ray confirmation and for collection of two 
sets of pre-treatment blood cultures. Thus, two pairs of blood cul-
tures for both aerobic and anaerobic conditions were collected and 
processed using an automated colorimetric detection system (BacT/
ALERT, bioMerieux, Durham, NC, USA) in three hospitals and an 
equivalent blood culture system (BACTEC Becton-Dickinson, Cock-
eysville, MD, USA) in the other three hospitals [12]. If blood culture 
bottles indicated bacterial growth, samples were Gram stained and 
subcultured. The correct identification of the pathogen was achieved 
according to routine laboratory procedures. There was no recom-
mendation for or against viral testing as the main trial focus was on 
bacterial CAP.
Inclusion criteria for patients were: written informed consent, 
age  ≥  18 years, and admission from the community or a nursing home 
with the main diagnosis of CAP. Exclusion criteria were the inability 
to provide written informed consent, insufficient German language 
skills, active intravenous drug use, previous hospitalization within 
14 days, severe immunosuppression other than that induced by cor-
ticosteroids, accompanying chronic infection or endocarditis, and 
severe medical co-morbidity where death was imminent. Diagnosis 
of CAP required the presence of at least one respiratory symptom 
(cough with or without sputum production, dyspnea, tachypnea, or 
pleuritic chest pain) in addition to one auscultatory finding or sign 
of infection (core body temperature  > 38.0 °C, shivers, or white blood 
count  > 10 g/L or  < 4 g/L cells) and a new infiltrate on chest radio-
graph [6].
In all patients, baseline assessments included collection of 
clinical data and vital signs, confirmation of the presence or absence 
of comorbid conditions, and a routine blood test. Patients were fol-
lowed during the hospital stay and blood specimens were sampled 
for PCT, CRP, and WBCs upon hospital admission, on days 3, 5 and 7, 
and on the day of discharge. Serum PCT was measured with a highly 
sensitive time-resolved amplified cryptate emission (TRACE) technol-
ogy assay (PCT Kryptor, B.R.A.H.M.S. AG, Hennigsdorf, Germany). 
The assay has a detection limit of 0.02 μg/L and a functional assay 
sensitivity of 0.06 μg/L (i.e., 3- to 10-fold above normal mean values). 
Serum CRP concentrations were determined by an enzyme immuno-
assay having a detection limit of  < 5 mg/dL (EMIT, Merck Diagnostica, 
Zurich, Switzerland). The CURB-65 score was calculated at admission 
in all patients as recommended [13, 14].
We performed blinded telephone interviews with all patients 
30 days after inclusion for assessment of vital status and other sec-
ondary endpoints.
Statistical considerations and analysis
The primary endpoint of this analysis was all-cause mortality within 
30 days. Secondary endpoints included serious adverse events 
defined as death or intensive care unit (ICU) admission.
Discrete variables are expressed as counts (percentage) and 
continuous variables as medians and interquartile ranges (IQR). 
Frequency comparison was done using the χ2-test. The two-group 
comparison for continuous data was done with the Mann-Whitney 
U-test. We used univariate and multivariate logistic regression analy-
sis to study the association between biomarker levels and outcome 
adjusting the models for the CAP severity score CURB-65 [15]. Area 
under the receiver-operating-characteristics curve (AUC) was calcu-
lated to assess overall discrimination using STATA 9.2 (Stata Corp, 
College Station, TX, USA). All statistical tests were two-tailed and 
p-values  < 0.05 were considered to indicate statistical significance.
Results
This analysis includes 925 patients with a final diagnosis 
of CAP. The median age was 73  years and most patients 
suffered from at least one comorbidity including chronic 
heart failure (17%), cerebrovascular disease (9%), diabe-
tes (17%), and chronic renal failure (23%). Risk assess-
ment on admission showed that 50.4% of patients were 
in the high-risk CURB-65 category with scores of  ≥  2 
points. At the 30-day follow-up, 118 patients had a serious 
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Table 1 Baseline characteristics of the study participants (n = 925).
  All patients (925)   Survivors (875)   Non-survivors (50)   p-Value
Demographic characteristics
 Age, years   73 (59–82)   72 (57–82)   81 (75–85)    < 0.0001
 Sex (men), n (%)   544 (58.8)   511 (58.4)   33 (66.0)   0.28
Coexisting illnesses, n (%)
 Chronic heart failure   159 (17.2)   143 (16.3)   16 (32.0)   0.0043
 Cerebrovascular disease   82 (8.9)   77 (8.8)   5 (10.0)   0.7718
 Renal dysfunction   206 (22.3)   177 (20.2)   29 (58.0)    < 0.0001
 Neoplastic disease   118 (12.8)   107 (12.2)   11 (22.0)    < 0.05
 Diabetes   162 (17.5)   152 (17.4)   10 (20.0)   0.63
Complains, n (%)
 Cough   762 (82.4)   721 (82.4)   41 (82.0)   0.14
 Sputum production   437 (47.2)   409 (46.7)   28 (56.0)   0.08
 Dyspnea   696 (75.2)   654 (74.7)   42 (84.0)   0.0006
 Fever   618 (66.8)   595 (68.0)   23 (46.0)   0.001
 Chills   301 (32.5)   291 (33.3)   10 (20.0)   0.079
Clinical findings
 Confusion, n (%)   74 (8.0)   64 (7.3)   10 (20.0)   0.003
 Respiratory rate, breaths/min   20 (16–25)   20 (16–25)   24 (19–30)   0.02
 Systolic blood pressure, mmHg   132 (119–148)   132 (120–149)   120 (100–140)    < 0.01
 Heart rate, beats/min   95 (82–108)   95 (82–108)   98 (75–108)   0.35
 Body temperature, °C   38.1 (37.2–38.9)   38.1 (37.3–38.9)   37.4 (36.7–38.6)    < 0.01
 Rales, n (%)   894 (96.6)   599 (68.5)   37 (74.0)   0.24
Laboratory findings
 Procalcitonin (PCT), ng/L   0.46 (0.15–2.66)   0.46 (0.15–2.61)   0.83 (0.30–5.66)   0.023
 C-reactive protein, mg/dL   155 (75–252)   155.5 (74.4–252)   153 (75–258)   1.0
 White blood cells, WBC   12 (9–16.4)   12 (9–16.4)   12.2 (9.5–16.9)   0.72
CURB-65 scores
 0–1   459 (49.6)   450 (51.4)   9 (18.0)    < 0.001
 2   306 (33.1)   284 (32.5)   22 (44.0)   0.092
 3–4   160 (17.3)   141 (16.1)   19 (38.0)    < 0.001
CURB-65, confusion, urea, respiratory, blood pressure, age 65 years or older.
adverse event defined as mortality (35 patients, 3.8%), ICU 
admission (68 patients, 7.4%) or both (15 patients, 1.6%). 
Table 1 shows pertinent patient characteristics of the 
overall cohort and categorized by survival status. Admis-
sion PCT levels were significantly higher in non-survivors 
as compared to survivors [0.83 ng/L (IQR 0.30–5.66) vs. 
0.46 (IQR 0.15–2.61); p = 0.023]. There was no difference 
between these two groups with regard to admission CRP 
and WBC levels.
We used univariate and multivariate logistic regres-
sion models to investigate associations between admis-
sion and follow-up biomarker levels and outcome 
(Table 2). In univariate analysis, admission PCT levels 
were significant predictors of 30-day mortality on admis-
sion [unadjusted odds ratio (OR) per unit increase of 
log transformed PCT 1.19 (95% CI 1.03–1.38); AUC 0.60]. 
However, this association was no longer significant after 
adjustment for the CURB-65 score. No significant associa-
tion of admission CRP levels [unadjusted OR 1.01 (95% 
0.77–1.33); AUC 0.45] or WBC counts [unadjusted OR 1.01 
(95% 0.56–1.86); AUC 0.52] with outcome was found.
Consideration of follow-up biomarker levels and kinet-
ics of the biomarkers from admission through days 3, 5, and 
7 revealed all biomarkers as having a better association 
with outcome compared to initial levels alone (Table 2). 
The AUC of PCT was 0.61, 0.68, and 0.73 at days 3, 5 and 7, 
respectively, while the differences in AUC between admis-
sion and these three time points were 0.69, 0.65, and 0.71, 
respectively. The corresponding results for CRP were 0.62, 
0.68, and 0.78 for days 3, 5 and 7, and 0.50, 0.44, and 0.62 
for the differences, respectively. For WBC, the AUC values 
were 0.67, 0.65, and 0.77 on days 3, 5, and 7, respectively, 
while the respective differences were 0.67, 0.58, and 0.79.
Table 3 shows the results of a similar analysis for 
serious adverse events. In this case, the prognostic poten-
tial for all biomarkers was better compared to survival 
prediction and was also significant after adjusting for the 
CURB-65 score.
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Finally, we also investigated the potential of the 
different markers assayed on admission and during fol-
low-up to improve prognostication performed using the 
clinical CURB-65 score alone. This was done by using 
multivariate logistic regression models to compare the 
AUC of the CURB-65 score alone with the AUC of the 
CURB-65 score in combination with levels of each bio-
marker individually and all together (Table 4). When 
looking at levels of these biomarkers at admission, PCT, 
CRP, and the combination of all biomarkers together 
improved the AUC of the CURB-65 score for prediction 
of adverse clinical outcome (from AUC 0.68 to 0.74). The 
same was not applicable for mortality prediction, where 
no significant improvements in AUC based on admis-
sion biomarker levels could be observed. Examination 
of improvements in AUC based on follow-up biomarker 
levels revealed the most significant improvements to 
have occurred on days 5 and 7 for both survival predic-
tion and adverse clinical outcome.
Discussion
The added value of prognostic information derived from 
inflammatory biomarkers in addition to established 
clinical scores remains a topic of debate, with multi-
ple smaller studies providing somewhat heterogeneous 
results. Viewed in this context, the findings of our study 
conducted in a large and well-characterized CAP cohort 
are important and provide information on the value not 
only of initial but also of follow-up biomarker levels. The 
main findings of this study are three-fold. First, initial bio-
marker levels provide only limited information to assist 
with mortality prediction and do not improve prognostic 
capacity of the CURB-65 score. Second, considering the 
kinetics of the markers, PCT, CRP and to a lesser degree 
WBC provide additional prognostic information for mor-
tality risk prediction. Third, all biomarkers combined and 
added to the CURB-65 score improve the ability to iden-
tify patients at risk for adverse clinical outcomes when 
Table 2 Association of biomarker levels and survival.
  Mortality
  Unadjusted OR (95%)   p-Valuea   AUC   Adjusted OR (95% CI)b   p-Valuea
Laboratory findings
PCT (per 10-fold increase)
 Day 1   1.19 (1.03–1.38)   0.019   0.595   1.06 (0.90–1.25)   0.439
 Day 3   1.26 (1.03–1.54)   0.023   0.609   1.14 (0.92–1.41)   0.222
 Day 5   1.40 (1.08–1.80)   0.009   0.680   1.30 (0.99–1.71)   0.056
 Day 7   1.69 (1.27–2.24)    < 0.001   0.733   1.67 (1.25–2.23)   0.001
Difference in PCT level from admission
 Day 3   1.35 (1.06–1.71)   0.013   0.688   1.31 (1.03–1.67)   0.030
 Day 5   1.23 (0.91–1.66)   0.178   0.649   1.22 (0.90–1.66)   0.204
 Day 7   1.43 (1.02–2.00)   0.038   0.707   1.42 (1.00–2.00)   0.044
CRP
 Day 1   1.01 (0.77–1.33)   0.933   0.450   0.99 (0.75–1.30)   0.933
 Day 3   1.51 (0.94–2.43)   0.090   0.621   1.40 (0.86–2.27)   0.171
 Day 5   1.95 (1.20–3.15)   0.007   0.680   1.92 (1.15–3.19)   0.013
 Day 7   3.31 (1.79–6.12)    < 0.001   0.780   3.46 (1.82–6.56)    < 0.001
Difference in CRP level from admission
 Day 3   1.00 (0.67–1.49)   0.995   0.503   1.02 (0.68–1.52)   0.939
 Day 5   0.84 (0.48–1.46)   0.530   0.438   0.85 (0.48–1.52)   0.585
 Day 7   1.61 (0.66–3.94)   0.297   0.622   1.38 (0.52–3.65)   0.513
WBC
 Day 1   1.01 (0.56–1.86)   0.954   0.515   0.98 (0.54–1.80)   0.971
 Day 3   2.80 (1.56–5.05)   0.001   0.665   2.65 (1.14–2.82)   0.002
 Day 5   3.17 (1.51–6.67)   0.002   0.653   2.89 (1.29–6.48)   0.010
 Day 7   8.43 (2.50–28.37)   0.001   0.773   8.12 (2.42–27.25)   0.001
Difference in WBC level from admission
 Day 3   1.56 (0.94–2.58)   0.083   0.672   1.73 (0.98–3.04)   0.059
 Day 5   1.28 (0.75–2.19)   0.371   0.579   1.27 (0.73–2.19)   0.397
 Day 7   3.88 (1.23–12.23)   0.020   0.794   3.74 (1.21–11.61)   0.022
AUC, area under the curve; CRP, C-reactive protein; OR, odds ratio; PCT, procalcitonin; WBC, white blood cells. ap-Values are derived from 
the χ2-test; bAdjusted for CURB-65.
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Table 3 Association of biomarker levels and adverse clinical outcomes.
  Death and ICU admission
  Odds ratio (95%)   p-Valuea   AUC   Adjusted OR   Adjusted p-Value
Laboratory findings
PCT
 Day 1   1.34 (1.21–1.49)    < 0.001   0.655   1.25 (1.12–1.40)    < 0.001
 Day 3   1.44 (1.27–1.64)    < 0.001   0.674   1.37 (1.20–1.57)    < 0.001
 Day 5   1.64 (1.41–1.92)    < 0.001   0.711   1.57 (1.34–1.84)    < 0.001
 Day 7   1.72 (1.44–2.05)    < 0.001   0.695   1.67 (1.40–2.00)    < 0.001
Difference in PCT level from admission
 Day 3   1.37 (1.16–1.62)    < 0.001   0.693   1.34 (1.13–1.59)   0.001
 Day 5   1.60 (1.25–2.06)    < 0.001   0.782   1.59 (1.24–2.05)    < 0.001
 Day 7   1.56 (1.21–2.03)   0.001   0.764   1.56 (1.20–2.03)   0.001
CRP
 Day 1   1.61 (1.27–2.04)    < 0.001   0.638   1.59 (1.26–2.02)    < 0.001
 Day 3   1.97 (1.44–2.70)    < 0.001   0.663   1.90 (1.39–2.62)    < 0.001
 Day 5   2.05 (1.53–2.74)    < 0.001   0.679   2.03 (1.50–2.75)    < 0.001
 Day 7   1.76 (1.36–2.28)    < 0.001   0.661   1.75 (1.35–2.28)    < 0.001
Difference in CRP level from admission
 Day 3   1.14 (0.83–1.57)   0.423   0.544   1.16 (0.83–1.60)   0.385
 Day 5   1.19 (0.74–1.91)   0.467   0.561   1.22 (0.75–1.97)   0.420
 Day 7   1.30 (0.65–2.61)   0.463   0.557   1.21 (0.59–2.49)   0.606
WBC
 Day 1   0.86 (0.57–1.29)   0.461   0.494   0.83 (0.55–1.25)   0.376
 Day 3   2.27 (1.48–3.49)    < 0.001   0.630   2.19 (1.40–3.41)   0.001
 Day 5   4.18 (2.35–7.39)    < 0.001   0.709   4.21 (2.32–7.65)    < 0.001
 Day 7   5.49 (2.72–11.10)    < 0.001   0.701   5.42 (2.66–11.03)    < 0.001
Difference in WBC level from admission
 Day 3   1.28 (0.90–1.82)   0.164   0.590   1.38 (0.93–2.03)   0.106
 Day 5   1.39 (1.00–1.94)   0.049   0.623   1.42 (1.01–2.00)   0.047
 Day 7   1.51 (0.99–2.31)   0.054   0.633   1.50 (0.98–2.29)   0.064
Adjusted OR, odds ratio adjusted for CURB-65; Adjusted p-Value, p-Value adjusted for CURB-65; AUC, area under the curve; CRP, C-reactive 
protein; ICU, intensive care unit; PCT, procalcitonin; WBC, white blood cells. ap-Values are derived from the χ2-test.
compared with the CURB-65 score alone, both on admis-
sion and to a greater extent if the kinetics of these bio-
markers over time are also considered.
Respiratory infection management guidelines recom-
mend stratifying patients with CAP based on the predicted 
risk of mortality using risk scores, such as the CURB-65 
[13, 15, 16]. However, clinical risk scores are somewhat 
limited in their practicality in routine clinical practice and 
carry the risk of miscalibration due to different patient 
populations and therefore have only moderate opera-
tional utility [17]. As a consequence, there is heightened 
interest in the development of additional prognostication 
parameters based on newly identified biomarkers that are 
objectively and rapidly measurable, responsive to clinical 
recovery, and add relevant, reliable, and real-time infor-
mation [18–20]. Different studies have evaluated the prog-
nostic potential of PCT in patients with CAP [20–25]. Some 
of these studies have found that PCT levels only have 
moderate prognostic accuracy with regard to prediction 
of mortality. In a large study from the US, most of the 
benefit of adding PCT levels to existing prediction rules 
was found in patients with high risk as assessed using 
a clinical severity score (the PSI) [23]. A low PCT level 
( < 0.1 mg/L) almost always excluded mortality in high-
risk patients. A previous Swiss study using the ProHOSP 
patient cohort showed that simply measuring the initial 
PCT level did not improve clinical score for mortality but 
that following the kinetics of PCT did so, with falling levels 
demonstrating improved clinical outcomes during follow-
up [26]. The same study found that PCT can better predict 
serious events, such as ICU admission and complications 
of CAP (e.g., empyema). As a predictor of these outcomes, 
PCT could significantly improve clinical risk scores such 
as the PSI and CURB-65, a finding that was confirmed by 
our results. A study of low-risk CAP patients showed PCT 
to be a good predictor of mortality and to also significantly 
improve clinical risk scores [21]. The current report further 
extends the findings of these studies by also comparing 
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PCT to other inflammatory markers and their combination 
with clinical CAP risk scores.
Similar to our findings but with more statistical power, 
a large study from Germany including 1671 CAP patients 
found that PCT levels at admission predict the outcome 
of CAP with a similar prognostic accuracy as the CRB-65 
score and with a higher prognostic accuracy compared 
with CRP and WBC [27]. The AUC for mortality for PCT 
was 0.80 (95% CI 0.75–0.84), as compared to an AUC of 
0.79 (0.74–0.84) for CRB-65, 0.62 (0.54–0.68) for CRP, and 
Table 4 Prognostic value of the CURB-65 score alone and in combi-
nation with biomarker levels.
Biomarkers     Mortality   Adverse clinical 
outcomes
  n total   AUC (95% CI)   AUC (95% CI)
Day 1
 CURB-65   917   0.72 (0.66–0.78)   0.68 (0.64–0.73)
 CURB-65+PCT   917   0.73 (0.67–0.79)   0.71 (0.66–0.76)
 CURB-65+CRP   917   0.72 (0.66–0.78)   0.73 (0.68–0.78)
 CURB-65+WBC   917   0.73 (0.67–0.79)   0.68 (0.63–0.73)
 All   917   0.73 (0.67–0.79)   0.74 (0.69–0.78)
Day 3
 CURB-65+PCT   644   0.74 (0.66–0.83)   0.71 (0.65–0.77)
 CURB-65+CRP   644   0.74 (0.65–0.83)   0.73 (0.67–0.80)
 CURB-65+WBC   644   0.76 (0.69–0.84)   0.68 (0.62–0.74)
 All   644   0.76 (0.68–0.84)   0.75 (0.69–0.81)
Day 5
 CURB-65+PCT   464   0.71 (0.62–0.81)   0.75 (0.70–0.81)
 CURB-65+CRP   464   0.71 (0.60–0.83)   0.76 (0.69–0.82)
 CURB-65+WBC   464   0.69 (0.58–0.80)   0.74 (0.68–0.80)
 All   464   0.73 (0.63–0.83)   0.79 (0.74–0.84)
Day 7
 CURB-65+PCT   371   0.77 (0.65–0.89)   0.71 (0.64–0.78)
 CURB-65+CRP   371   0.82 (0.72–0.92)   0.68 (0.61–0.76)
 CURB-65+WBC   371   0.74 (0.62–0.86)   0.72 (0.66–0.79)
 All   371   0.85 (0.80–0.93)   0.75 (0.68–0.81)
Difference day 1–3
 CURB-65+PCT   640   0.68 (0.58–0.78)   0.54 (0.47–0.62)
 CURB-65+CRP   640   0.63 (0.53–0.72)   0.52 (0.46–0.59)
 CURB-65+WBC   640   0.70 (0.59–0.81)   0.69 (0.62–0.75)
 All   640   0.78 (0.71–0.85)   0.70 (0.63–0.76)
Difference day 1–5
 CURB-65+PCT   461   0.65 (0.50–0.79)   0.55 (0.47–0.64)
 CURB-65+CRP   461   0.72 (0.60–0.85)   0.60 (0.53–0.68)
 CURB-65+WBC   461   0.61 (0.49–0.74)   0.71 (0.64–0.77)
 All   461   0.70 (0.59–0.80)   0.74 (0.68–0.80)
Difference day 1–7
 CURB-65+PCT   369   0.62 (0.45–0.79)   0.50 (0.41–0.59)
 CURB-65+CRP   369   0.79 (0.66–0.92)   0.54 (0.46–0.62)
 CURB-65+WBC   369   0.62 (0.43–0.81)   0.69 (0.62–0.76)
 All   369   0.76 (0.67–0.86)   0.71 (0.64–0.79)
All, CURB-65+PCT+CRP+WBC; AUC, area under the curve; 95% CI, 
95% confidence intervals; CRP, C-reactive protein; ICU, intensive 
care unit; PCT, procalcitonin; WBC, white blood cells.
0.61 (0.54–0.68) for WBC. This study also documented the 
added utility of PCT in the identification of patients at very 
low risk of death despite increased CRB-65 scores. Another 
study from France that included 100 patients admitted to 
the ICU with CAP reported that increased PCT from day 1 
to day 3 in patients with severe CAP is suggestive of a poor 
prognosis and a PCT level  < 0.95 ng/mL on day 3 in intu-
bated patients is associated with a better outcome [28]. 
The kinetics of biomarkers on follow-up also has addi-
tional prognostic accuracy in our study. The CRP value for 
mortality was not informative, contrary to the findings of 
a previous study [7].
Improved prediction of 30-day mortality in CAP 
patients by using a combination of CRP in conjunction 
with the PSI, CURB-65, and CRB65 clinical severity indices 
has also been described [7]. We did not find a significant 
correlation of CRP levels at admission with outcome and 
can confirm the results of other studies documenting the 
poor prognosis value of CRP levels [29, 30]. Kruger et al. 
found PCT, CRP, and WBC to be predictive of 28-day mor-
tality exclusively in patients without antimicrobial pre-
treatment [21].
Our study had limitations. This cohort included mainly 
inpatients. Therefore it is not possible to determine whether 
the results would also be applicable to lower risk outpatients 
with CAP. Quantification of PCT levels on days 3, 5, and 7 
was based on patient availability and contributed to infor-
mation not being complete in the case of a few patients. The 
potential impact of antimicrobial pre-treatment on marker 
levels was not considered in this analysis. More over, this 
was a secondary analysis of a previously published ran-
domized study, and exclusion criteria and the resulting 
non-participation of some patients may limit the external 
validity of our findings. Specifically, patients with immu-
nosuppression and chronic infection were not included, 
which limits the generalizability of our results in regard to 
this important patient population. Finally, our study was 
an observational, exploratory study and, thus, hypothesis 
generating. Future interventional studies should ultimately 
test the potential of a biomarker-enhanced clinical risk 
score strategy on patient outcomes. As good examples in 
this regard, two recently published trials found improved 
outcomes following use of the inflammatory biomarker 
ProADM (ProAdrenomedullin) in addition to CURB-65 to 
facilitate site-of-care decisions in CAP [31, 32].
Conclusions
This study demonstrated that PCT, and to a lesser degree 
CRP, provide prognostic information on CAP outcomes, 
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particularly when their kinetics are taken into considera-
tion and when adverse clinical outcomes are also con-
sidered instead of mortality alone. The most important 
improvements were found on days 5 and 7 for prediction 
of both survival and adverse clinical outcomes. Future 
randomized trials should assess whether integration of 
initial and follow-up biomarker levels results in improved 
decision making by physicians regarding initial site of 
care and early discharge from the hospital.
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